Prostate Cell News Volume 14.30 | Aug 11 2023

    By
    Laurisa Dohm
    -
    0
    19








    2023-08-11 | PCN 14.30


    Prostate Cell News by STEMCELL Technologies
    Vol. 14.30 – 11 August, 2023
    TOP STORY

    PLEKHS1 Drives PI3Ks and Remodels Pathway Homeostasis in PTEN-Null Prostate

    Investigators found that in healthy mouse prostate phosphoinositide 3-kinase (PI3K) activity was driven by receptor tyrosine kinase/IRS signaling and constrained by pathway feedback.
    [Molecular Cell]

    Full ArticleGraphical Abstract
    Guide to everything you need to know about cell separation.
    PUBLICATIONSRanked by the impact factor of the journal

    AR Antagonists Develop Drug Resistance through TOMM20 Autophagic Degradation-Promoted Transformation to Neuroendocrine Prostate Cancer

    The impact of translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) depletion on drug sensitivity were elucidated by assays of cell proliferation, invasion, sphere formation, xenograft growth, and intravenous metastasis.
    [Journal Of Experimental & Clinical Cancer Research]

    Full Article

    Therapeutic Implications for Localized Prostate Cancer by Multiomics Analyses of the Aging Microenvironment Landscape

    An aging microenvironment index was constructed, with excellent prognostic and immunotherapy prediction ability, and its clinical relevance was surveyed through spatial transcriptomics.
    [International Journal Of Biological Sciences]

    Full ArticleGraphical Abstract

    ASCL1 Is Activated Downstream of the ROR2/CREB Signaling Pathway to Support Lineage Plasticity in Prostate Cancer

    A survey of receptor tyrosine kinases (RTKs) identified ROR2 as the top upregulated RTK following androgen receptor pathway inhibition, which fed into lineage plasticity by promoting stem-cell-like and neuronal networks.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Low-Dose Antimony Exposure Promotes Prostate Cancer Proliferation by Inhibiting Ferroptosis via Activation of the Nrf2-SLC7A11-GPX4 Pathway

    Investigators demonstrated that antimony exposure promoted prostate cancer progression in vivo and in vitro.
    [Chemosphere]

    AbstractGraphical Abstract

    Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer

    A representative compound, BWA-522, effectively induced degradation of both androgen receptor-FL and androgen receptor-V7, and was more potent than the corresponding antagonist against prostate cancer cells in vitro.
    [Journal Of Medicinal Chemistry]

    AbstractGraphical Abstract

    Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer

    Researchers validated the utility and selectivity of the compounds developped in cell-based models of prostate cancer.
    [Journal Of Medicinal Chemistry]

    AbstractGraphical Abstract

    m6A-Modified circABCC4 Promotes Stemness and Metastasis of Prostate Cancer by Recruiting IGF2BP2 to Increase Stability of CCAR1

    Investigators found that circABCC4 was highly expressed in prostate cancer (PCa) tissues and cells, and elevated circABCC4 level indicated a poor overall survival of PCa patients.
    [Cancer Gene Therapy]

    Abstract

    Taraxasterol Suppresses the Proliferation and Tumor Growth of Androgen-Independent Prostate Cancer Cells through the FGFR2-PI3K/AKT Signaling Pathway

    Scientists found that taraxasterol could significantly suppress the viability and growth of androgen-independent prostate cancer cells and down-regulate the expression of c-Myc and cyclin D1 in vitro.
    [Scientific Reports]

    Full Article
    View tips on how to organize your lab notebooks, references and protocols.
    REVIEWS

    An Overview of Hormonal Directed Pharmacotherapy for the Treatment of Prostate Cancer

    The authors review the literature regarding hormonal-directed therapy prostate cancer.
    [Expert Opinion On Pharmacotherapy]

    Abstract
    INDUSTRY AND POLICY NEWS

    Arcus, Gilead Drop A2R Inhibitor in Prostate Cancer after Glimpsing Early Data

    Arcus Biosciences and Gilead have decided not to advance their A2R inhibitor in prostate cancer after taking a look at some early clinical data. The two companies are studying the candidate, called etrumadenant, in trials of various cancers in combination with chemo and other drugs.
    [Fierce Biotech]

    Press Release
    FEATURED EVENT

    5th TIL Therapies Summit

    October 2 – 4, 2023
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – Prostate Cancer Metastasis

    Stony Brook University – Stony Brook, New York, United States

    Postdoctoral Fellow – Prostate Cancer Research

    Georgia Cancer Center at Augusta University – Augusta, Georgia, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    Postdoctoral Scholar – Human Androgen Receptor

    The University of Iowa – Iowa City, Iowa, United States

    Senior Clinical Scientist – Oncology

    Debiopharm – Lausanne, Switzerland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter